Influence of prostaglandin E2 and indomethacin on interferon-? production by cultured peripheral blood leukocytes of multiple sclerosis patients and healthy donors

1985 ◽  
Vol 5 (2) ◽  
pp. 102-108 ◽  
Author(s):  
Greta Vervliet ◽  
Hans Deckmyn ◽  
Herwig Carton ◽  
Alfons Billiau
Keyword(s):  
Multiple Sclerosis ◽  
Prostaglandin E2 ◽  
Peripheral Blood ◽  
Interferon Production ◽  
Peripheral Blood Leukocytes ◽  
Blood Leukocytes ◽  
Healthy Donors ◽  
Multiple Sclerosis Patients

scholarly journals Expression of DROSHA and DICER genes in peripheral blood leukocytes in lung sarcoidosis

2018 ◽  
Vol 90 (3) ◽  
pp. 21-24
Author(s):  
I E Malysheva ◽  
O V Balan ◽  
E L Tikhonovich ◽  
T O Volkova
Keyword(s):  
Gene Expression ◽  
Polymerase Chain Reaction ◽  
Real Time ◽  
Peripheral Blood ◽  
Messenger Rna ◽  
Peripheral Blood Leukocytes ◽  
Chain Reaction ◽  
Blood Leukocytes ◽  
Healthy Donors ◽  
Polymerase Chain

Aim. To study the expression level of the genes DROSHA and DICER in peripheral blood leukocytes (PBL) of patients with sarcoidosis of the lungs Materials and methods. The study included 32 patients diagnosed with persistent lung sarcoidosis (mean age 41.56±1.27 years) and 36 healthy donors (control; mean age 42.79±1.95 years). The level of expression of messenger RNA (mRNA) of the genes DROSHA and DICER were determined in PBL of healthy donors and patients with sarcoidosis of the lung by polymerase chain reaction in real time. Results. As a result of the conducted researches it is established that the level of drosha gene expression in PBL patients with sarcoidosis of lungs is significantly reduced in comparison with the control (p

scholarly journals Hyperexpression of TLR2 and TLR4 in patients with ischemic stroke in acute period of the disease

2020 ◽  
Vol 22 (4) ◽  
pp. 665-674
Author(s):  
L. V. Gankovskaya ◽  
L. V. Stakhovskaya ◽  
V. V. Grechenko ◽  
E. A. Koltsova ◽  
O. S. Uvarova ◽  
...  
Keyword(s):  
Gene Expression ◽  
Innate Immunity ◽  
Ischemic Stroke ◽  
Peripheral Blood ◽  
Surface Expression ◽  
Control Group ◽  
Peripheral Blood Leukocytes ◽  
Blood Leukocytes ◽  
Healthy Donors ◽  
Tlr4 Gene

Pathogenesis of ischemic stroke  is actively  involved  in the  system  of innate immunity. Under conditions of cerebral  ischemia, a number of biologically  active  substances are  released  that  interact with innate immunity receptors, in particular TLR2  and  TLR4, which  exacerbate inflammation in brain  tissue. Identification of predictor markers  at the level of the innate immunity system may foresee the clinical course of ischemic stroke and ensure timely treatment. Our objective was to study expression of TLR2 and TLR4 receptors in peripheral blood leukocytes  in patients with ischemic stroke in the dynamics of the disease. 27 people  were included in the study. The main  group consisted of patients with ischemic stroke of varying severity (n = 19). Patients of the main  group were divided into two subgroups:  with an NIHSS index value of < 10 (n = 10) and > 10 (n = 9). The control group included healthy  donors  with no history  of acute  and chronic inflammatory diseases (n = 8). Peripheral blood  leukocytes  were used as the  test material. To determine expression  of the TLR2  and TLR4  genes, RT-PCR in real time was used. Surface  expression  of TLRs was determined by flow cytometry. A study of the TLR2 and TLR4 gene expression showed that on the 1st, 3rd  and 7th  day post-stroke, the TLR4 gene expression  in patients was significantly  increased, when compared to the control group (p < 0.01), whereas TLR2 gene expression on the 3rd  day of the disease was not statistically different from the control group. A study of surface expression  of receptors showed that the average TLR2 fluorescence intensity on the patients’ peripheral blood monocytes was significantly  increased on the 1st  and 3rd  day of disease when compared to the control group.  The  surface  expression  of TLR4  on monocytes has a statistically significant  increase  only on day 7. Assessment  of surface expression  of TLRs in subgroups  with different  severity values by NIHSS showed that  patients with a NIHSS index > 10 had a significantly  higher  level of surface of TLR2  expression  over the observation period, while the largest difference in TLR4  expression  in the subgroups  was observed  on the 1st day of the disease (p < 0.05). Patients with ischemic stroke showed an increase  in TLR2 and TLR4 expression at the gene and protein level, compared to healthy  donors. These indices can be considered possible predictors for clinical  prognosis  of ischemic stroke.

Deficiency in Interferon Production of Peripheral Blood Leukocytes from Patients with Non-Hodgkin Lymphoma

1992 ◽  
Vol 1992 (special_issue) ◽  
pp. 61-69 ◽  
Author(s):  
ANTHONY D. HO ◽  
THOMAS MORITZ ◽  
KARIN RENSCH ◽  
WERNER HUNSTEIN ◽  
HOLGER KIRCHNER
Keyword(s):  
Hodgkin Lymphoma ◽  
Peripheral Blood ◽  
Interferon Production ◽  
Peripheral Blood Leukocytes ◽  
Blood Leukocytes ◽  
Non Hodgkin Lymphoma

Deficiency in Interferon Production of Peripheral Blood Leukocytes from Patients with Non-Hodgkin Lymphoma

1988 ◽  
Vol 8 (4) ◽  
pp. 405-413 ◽  
Author(s):  
ANTHONY D. HO ◽  
THOMAS MORITZ ◽  
KARIN RENSCH ◽  
WERNER HUNSTEIN ◽  
HOLGER KIRCHNER
Keyword(s):  
Hodgkin Lymphoma ◽  
Peripheral Blood ◽  
Interferon Production ◽  
Peripheral Blood Leukocytes ◽  
Blood Leukocytes ◽  
Non Hodgkin Lymphoma

scholarly journals Association of FOXP3 gene -3279 C>A polymorphism with the risk of pulmonary sarcoidosis

2017 ◽  
Vol 89 (12) ◽  
pp. 64-67 ◽  
Author(s):  
I E Malysheva ◽  
L V Topchieva ◽  
E L Tikhonovich ◽  
I V Kurbatova ◽  
O V Balan
Keyword(s):  
Peripheral Blood ◽  
Polymorphic Marker ◽  
Pulmonary Sarcoidosis ◽  
Control Group ◽  
Peripheral Blood Leukocytes ◽  
Blood Leukocytes ◽  
Foxp3 Gene ◽  
Healthy Donors ◽  
Gene Transcripts ◽  
The Republic

Aim. To investigate the association of the polymorphic marker -3279 C>A of the FOXP3 gene with the risk of pulmonary sarcoidosis (PS) and to estimate the transcription level of this gene in the carriers of different genotypes of this polymorphic marker. Subjects and methods. The investigation included 99 patients of Russian ethnicity (mean age, 45.41±1.31 years) living in the Republic of Karelia, who were diagnosed with persistent PS, and 116 healthy donors (mean age, 42.06±1.30 years) in the control group. The alleles and genotypes of the polymorphic marker -3279 C>A of the FOXP3 gene were identified using polymerase chain reaction (PCR)-restriction fragment length polymorphism. The number of transcripts of the studied gene in the peripheral blood leukocytes of healthy donors and PS patients was determined with real-time PCR. Results. The control group and the PS patient one had no statistically significant differences in the distribution of the frequencies of alleles and genotypes by the polymorphic marker –308G>A of the FOXP3 gene (p > 0.05). The number of FOXP3 gene transcripts was not statistically significantly different in the peripheral blood leukocytes of patients with PS and control individuals. No statistically significant differences were observed in the mRNA expression levels in the above-mentioned gene in the carriers of different genotypes by the polymorphic marker -3279 C>A of the FOXP3 gene in all examined groups. Conclusion. The polymorphic marker -3279 C>A of the FOXP3 gene is unassociated with the risk of PS.

scholarly journals Massive Restrain of Cytotoxic B cells in the Peripheral Blood During Fingolimod and Natalizumab Treatments in Multiple Sclerosis Patients

2020 ◽  
Author(s):  
Vinícius de Oliveira Boldrini ◽  
Raphael Patrício da Silva Quintiliano ◽  
Adriel dos Santos Moraes ◽  
Carla Stella ◽  
Ana Leda Figueiredo Longhini ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
B Cells ◽  
T Lymphocytes ◽  
Peripheral Blood ◽  
Antibody Therapy ◽  
Healthy Donors ◽  
Relapsing Remitting ◽  
Anti Cd20 ◽  
Multiple Sclerosis Patients

Abstract Background Recently, the success of anti-CD20 monoclonal antibody therapy brought a new light over the role of B cells in multiple sclerosis (MS) pathogenesis. Due to the expression pattern of CD20 during B cells ontogeny, this role seems to be extended beyond the antibodies' production and secretion. Therefore, here we investigated whether not only classical cytotoxic CD8+ T lymphocytes but also non-classical cytotoxic B cells may occur in the peripheral blood from relapsing-remitting MS (RRMS) patients. Methods 104 RRMS patients during different treatment and 58 healthy donors were studied. CD19, GzmB, Runx3 and CD49d expression was assessed by flow cytometry analyses. Results Patients treated with Natalizumab (NTZ) showed an increased percentage of CD8+GzmB+ when compared to other MS therapies, untreated RRMS patients and healthy volunteers. Similarly, and unexpected, massive cytotoxic behavior of B cells CD19+GzmB+ was observed in RRMS patients during Fingolimod (FTY) and NTZ therapies when compared to Glatiramer, Interferonβ, untreated MS patients and healthy donors. Conclusions During different MS treatments, B cells exhibit cytotoxic behavior resembling CD8+ T lymphocytes. This data suggest a possible involvement of “cytotoxic” B cells during MS pathology. Monitoring cytotoxic subsets might become an available marker for the risk of relapses and even for accessing therapeutic effectiveness in MS patients.

Sign in / Sign up

Export Citation Format

Share Document